<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mefenamic acid: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mefenamic acid: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mefenamic acid: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10833" href="/d/html/10833.html" rel="external">see "Mefenamic acid: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709030"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious cardiovascular thrombotic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>
<p style="text-indent:-2em;margin-left:2em;">Mefenamic acid is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serious gastrointestinal bleeding, ulceration, and perforation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867443"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ponstan [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F192173"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Analgesic, Nonopioid;</li>
<li>
                        Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</li></ul></div>
<div class="block doa drugH1Div" id="F192143"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: Safety:</b> Use the lowest effective dose for the shortest duration of time. Avoid or use with caution in patients at risk for or with existing cardiovascular disease, GI disease, kidney impairment, chronic liver disease, or a bleeding diathesis due to greater risk for adverse events. Consider administering in combination with a proton pump inhibitor in patients at risk for GI bleeding (eg, taking dual antiplatelet therapy or an anticoagulant, ≥60 years of age, high doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060077','lexi-content-ref-19017521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060077','lexi-content-ref-19017521'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0aa64061-6e3a-4e32-801e-0989bd1fbc53">Abnormal uterine bleeding, nonacute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, nonacute (alternative agent) (off-label use): Note:</b> Not indicated for management of acute abnormal bleeding (ie, excessively heavy or prolonged bleeding that requires urgent evaluation). Alternative agent for patients who cannot or choose not to use hormonal therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaunitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaunitz.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>500 mg 3 times daily <b>or </b>500 mg once followed by 250 mg 4 times daily. Begin at the first sign of menses and continue for 2 to 3 days or until cessation of bleeding; maximum dose: 1.5 <b>g</b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31535715','lexi-content-ref-1872778','lexi-content-ref-Kaunitz.1','lexi-content-ref-16045528','lexi-content-ref-3123043','lexi-content-ref-1595797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31535715','lexi-content-ref-1872778','lexi-content-ref-Kaunitz.1','lexi-content-ref-16045528','lexi-content-ref-3123043','lexi-content-ref-1595797'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e869268c-ef62-438f-96df-0870b699a85a">Dysmenorrhea, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysmenorrhea, primary:</b>
<b>Oral:</b> Initial: 500 mg beginning at the onset of bleeding and associated symptoms, followed by 250 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>) <b>or</b> 500 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7816793','lexi-content-ref-15225193','lexi-content-ref-2620043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7816793','lexi-content-ref-15225193','lexi-content-ref-2620043'])">Ref</a></span>); usually not to exceed 3 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64461cd2-35b0-4f59-964c-2b859cd1c46f">Pain, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain, mild to moderate:</b>
<b>Oral:</b> Initial: 500 mg, then 250 mg every 6 hours as needed; usually not to exceed 1 week.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991390"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Avoid use in patients with preexisting renal disease and in patients with advanced renal disease.</p>
<p style="text-indent:-2em;margin-left:2em;">KDIGO 2012 guidelines provide the following recommendations for NSAIDs:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p></div>
<div class="block doha drugH1Div" id="F50988579"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment <i>prior to</i> treatment initiation: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adjustment may be necessary due to extensive hepatic metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity <i>during </i>treatment: Discontinue if clinical signs and symptoms of liver disease develop, or if systemic manifestations occur.</p></div>
<div class="block doe drugH1Div" id="F192144"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Unless alternative agents are ineffective and a gastroprotective agent can be administered, avoid short-term scheduled use in combination with corticosteroids, anticoagulants, or antiplatelet agents or chronic use with or without medications that increase risk for bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing; initiate dose at lower end of the dosing range.</p></div>
<div class="block dop drugH1Div" id="F192156"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64461cd2-35b0-4f59-964c-2b859cd1c46f">Pain, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain, mild to moderate: </b>Adolescents ≥14 years: Refer to adult dosing.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130257"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Avoid use in patients with preexisting renal disease and in patients with advanced renal disease.</p>
<p style="text-indent:-2em;margin-left:2em;">KDIGO 2012 guidelines provide the following recommendations for NSAIDs:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p></div>
<div class="block dohp drugH1Div" id="F51130258"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); however, adjustment may be necessary due to extensive hepatic metabolism.</p></div>
<div class="block adr drugH1Div" id="F192112"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class (NSAIDs) and may not be specifically reported for mefenamic acid.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac arrhythmia, edema, heart failure, hypertension, hypotension, palpitations, syncope, tachycardia, thrombosis, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, bullous pemphigoid (Shepherd 1986), diaphoresis, ecchymoses, erythema multiforme, exfoliative dermatitis, fixed drug eruption (Ouni 2021), pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hypoalbuminemia (Kaosombetwattna 2017), weight changes (including weight loss) (Kaosombetwattna 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, change in appetite, colitis (Kaosombetwattna 2017), constipation, diarrhea (Isaacs 1987; Kaosombetwattna 2017), dyspepsia, eructation, esophagitis, flatulence, gastritis, gastrointestinal disease (enteropathy [including atrophic mucosa, intestinal inflammation, villous atrophy, and villous blunting]) (Isaacs 1987; Kaosombetwattna 2017), gastrointestinal hemorrhage, gastrointestinal inflammation, gastrointestinal perforation (including esophageal perforation and intestinal perforation), gastrointestinal ulcer (including duodenal ulcer, esophageal ulcer, gastric ulcer, peptic ulcer) (Kaosombetwattna 2017; Katsinelos 1999), glossitis, heartburn, hematemesis, melena, nausea, pancreatitis (VanWalraven 1982), rectal hemorrhage, steatorrhea (Isaacs 1987), stomatitis, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, dysuria, hematuria, oliguria, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia (Kaosombetwattna 2017), aplastic anemia, eosinophilia, hemolytic anemia, leukopenia (Handa 1990), lymphadenopathy, neutropenia (Handa 1990), pancytopenia, prolonged bleeding time, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatitis, hepatotoxicity (idiosyncratic; Chalasani 2021), increased liver enzymes (including increased serum alanine aminotransferase and increased serum aspartate aminotransferase), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, drug reaction with eosinophilia and systemic symptoms, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, anxiety, asthenia, cerebrovascular accident, coma, confusion, depression, dizziness, drowsiness, hallucination, headache, insomnia, malaise, meningitis, nervousness, paresthesia, seizure, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (Redmond 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (secondary) (Vishwakarma 2009), blurred vision, choroidal detachment (Vishwakarma 2009), conjunctivitis, myopia (Vishwakarma 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment; tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Glomerulonephritis (Segasothy 1987), increased serum creatinine (Drury 1981), interstitial nephritis (Segasothy 1987), polyuria, renal failure syndrome (Segasothy 1987), renal papillary necrosis (Segasothy 1987)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, dyspnea, pneumonia, respiratory depression</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F192125"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mefenamic acid, or any component of the formulation; use in the setting of coronary artery bypass graft (CABG) surgery; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy (third trimester); breast-feeding; severe uncontrolled heart failure; active gastric, duodenal, or peptic ulcer; active gastrointestinal bleeding; cerebrovascular bleeding or other bleeding disorders; inflammatory bowel disease; severe hepatic impairment or active hepatic disease; severe renal impairment (CrCl &lt;30 mL/minute) or deteriorating renal disease; known hyperkalemia; adolescents &lt;18 years of age</p></div>
<div class="block war drugH1Div" id="F192109"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with "aspirin triad" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with nonsteroidal anti-inflammatory drug (NSAID) or aspirin therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events:<b> [US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including MI and stroke. Risk may occur early during treatment and may increase with duration of use.</b> Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors for cardiovascular disease; however, absolute incidence of serious cardiovascular thrombotic events (which may occur early during treatment) was higher in patients with known cardiovascular disease or risk factors and in those receiving higher doses. New onset hypertension or exacerbation of hypertension may occur (NSAIDs may also impair response to ACE inhibitors, thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention; use with caution in patients with edema. Avoid use in heart failure (FDA 2015). Avoid use in patients with recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; consider alternate therapies for patients at high risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug reaction with eosinophilia and systemic symptoms: Potentially serious, sometimes fatal, drug reaction with eosinophilia and systemic symptoms (DRESS), also known as multiorgan hypersensitivity reactions, has been reported with NSAIDs. Monitor for signs and symptoms (eg, fever, rash, lymphadenopathy, eosinophilia) in association with other organ system involvement (eg, hepatitis, nephritis, hematological abnormalities, myocarditis, myositis). Early symptoms of hypersensitivity reaction (eg, lymphadenopathy, fever) may occur without rash; discontinue therapy and further evaluate if DRESS is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI events: <b>[US Boxed Warning]: NSAIDs cause increased risk of serious GI inflammation, ulceration, bleeding, and perforation (may be fatal); elderly patients and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.</b>
<b>These events may occur at any time during therapy and without warning.</b> Avoid use in patients with active GI bleeding. In patients with a history of acute lower GI bleeding, avoid use of non-aspirin NSAIDs, especially if due to angioectasia or diverticulosis (Strate 2016). Use caution with a history of GI ulcers, concurrent therapy known to increase the risk of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic disease, coagulopathy, smoking, use of alcohol, or in the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; consider alternate therapies for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of GI complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (ACCF/ACG/AHA [Bhatt 2008]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; monitor patients with coagulation disorders or who are receiving anticoagulants closely. Anemia may occur; monitor patients on long-term NSAID therapy for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Rare (sometimes fatal) severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, hepatic failure) have occurred with NSAID use; discontinue immediately if clinical signs or symptoms of hepatic disease develop or if systemic manifestations occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics, ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Long-term NSAID use may result in renal papillary necrosis and other renal injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: NSAIDs may cause potentially fatal skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning; discontinue use at first appearance of skin rash (or any other sign of hypersensitivity).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary artery bypass graft surgery: <b>[US Boxed Warning]: Use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</b> Risk of MI and stroke may be increased with use following CABG surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustments may be necessary due to extensive hepatic metabolism. Patients with advanced hepatic disease are at an increased risk of GI bleeding with NSAIDs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Avoid use in patients with preexisting renal disease and in patients with advanced renal disease; monitor renal function closely if therapy must be initiated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>
<div class="block foc drugH1Div" id="F192119"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block geq drugH1Div" id="F192105"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F192127"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Mefenamic Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $17.33 - $17.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867444"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ponstan: 250 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block adm drugH1Div" id="F192122"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May administer with food to reduce GI upset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3783459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3783459'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613239"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May take with food if it causes an upset stomach.</p></div>
<div class="block meg drugH1Div" id="F7874885"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F73125%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPIA1P95WpE36put%2B1OqbhC%2FpOBVVJfOIBxrjnbodBxTKrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=9601" target="_blank">https://www.fda.gov/media/73125/download</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F192120"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysmenorrhea, primary:</b> Treatment of primary dysmenorrhea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain, mild to moderate:</b> Relief of mild to moderate pain in patients ≥14 years, when therapy will not exceed 1 week.</p></div>
<div class="block off-label drugH1Div" id="F57529457"><span class="drugH1">Use: Off-Label: Adult</span><p>Abnormal uterine bleeding, nonacute</p></div>
<div class="block mst drugH1Div" id="F192181"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ponstel may be confused with Pronestyl</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Mefenamic acid is identified in the Beers Criteria as a potentially inappropriate medication to be avoided for chronic use in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). In addition, avoid for short-term scheduled use in combination with oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents unless alternatives are ineffective and patient can receive concomitant gastroprotective agent (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F192169"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> UGT1A9</p></div>
<div class="block dri drugH1Div" id="F192114"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Ketorolac (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Mefenamic Acid may decrease the protein binding of Levothyroxine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.  Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Avoid coadministration of pralatrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).  Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider alternatives to this combination when possible. If the combination must be used, monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308129"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Nonsteroidal anti-inflammatory drugs may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those undergoing investigation of fertility.</p></div>
<div class="block pri drugH1Div" id="F9646045"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Mefenamic acid crosses the placenta (Mackenzie 1985).</p>
<p style="text-indent:0em;margin-top:2em;">The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Avoid maternal use of NSAIDs beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause premature closure of the ductus arteriosus, product labeling for mefenamic acid specifically states to avoid use starting at 30 weeks' gestation.</p></div>
<div class="block brc drugH1Div" id="F9646047"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Mefenamic acid may be present in breast milk.</p>
<p style="text-indent:0em;margin-top:2em;">The relative infant dose (RID) of mefenamic acid is 0.92% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 750 mg/day.</p>
<p style="text-indent:0em;margin-top:2em;">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:0em;margin-top:2em;">The RID of mefenamic acid was calculated using a breast milk concentration of 0.66 mcg/mL, providing an estimated infant dose via breast milk of 0.099 mg/kg/day. This milk concentration was obtained following maternal administration of oral mefenamic acid 500 mg followed by 250 mg 3 times a day to 10 lactating women; sampling occurred on postpartum days 2 through 4. Mefenamic acid concentration in breast milk ranged from 0.03 to 0.66 mcg/mL. The total concentration of mefenamic acid and metabolites in breast milk were measured in three patients (seven samples available) and ranged from 0.62 to 1.99 mcg/mL. Mefenamic acid was measurable in infant serum and urine with mean concentrations of 0.08 mcg/mL and 9.8 mcg/mL, respectively. In comparison, maternal serum samples ranged from 0.1 to 3.6 mcg/mL (Buchanan 1968).</p>
<p style="text-indent:0em;margin-top:2em;">Nonopioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred for breastfeeding patients who require pain control peripartum or for surgery outside of the postpartum period (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. Avoid maternal use of NSAIDs if the breastfeeding infant has platelet dysfunction, thrombocytopenia, or a ductal-dependent cardiac lesion (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]; Bloor 2013).</p></div>
<div class="block mop drugH1Div" id="F45854769"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, chemistry profile, occult blood loss, and periodic liver function tests; renal function (urine output, serum BUN and creatinine); signs or symptoms of GI bleeding; blood pressure.</p></div>
<div class="block pha drugH1Div" id="F192108"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties.</p>
<p style="text-indent:0em;margin-top:2em;">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees) include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels. </p></div>
<div class="block phk drugH1Div" id="F192124"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapidly absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 1.06 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &gt;90% to albumin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via CYP2C9 to metabolites (activity not known)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~52%) and feces (~20%) as unchanged drug and metabolites</p></div>
<div class="block phksp drugH1Div" id="F51159443"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The potential exists for mefenamic acid metabolites to accumulate.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The potential exists for mefenamic acid metabolites to accumulate.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F192128"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fenam | Fendol ds | Mafepain | Neomef | Ponstan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ponstil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Konafen | Mefenabene | Mefenam | Parkakut | Parkemed</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Femin | FEMIN mefenamic acid | Mefic | Ponstan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Amifen | Dysmen | Fenamic | Fenaton | Flunil | Hpr | Mefalgin | Mefepain | Mefnac | Myfocin | Phental | Pontil</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Ponstyl</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acido mefenamico | Mefenan | Ponsdril | Ponstan | Pontin | Pontrex | Standor</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mefe-basan | Mefenacid | Mefenamin pfizer | Mefenaminacid Cime | Melur | Mephadolor | Ponstan | Spiralgin | Sportusal tabs</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Mefenal | Ponstyl | Ponstyl fort | Zopan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acido mefenamico | Algex | Algifemin | Dolcin | Flipal | Sicadol | Tanston | Templadol | Truasinol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jia fen | Mai fen ke</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acido mefenamic.mk | Acido mefenamico | Mefen | Mefenal | Ponstan | Posgen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ponalar</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acido mefenamico | Dolomef | Doloprin | Kalmadol | Lapontan | Mefac | Mefenac | Ponstan | Postagesic | Ptanfebrit | Sicadol | Xyclan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ponstan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Parkemed</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Farostan forte | Mafepain | Mefenam | Mefentan | Mefronil | Ponagic forte | Pono | Ponstan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Coslan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ponstan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ponstyl</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Contraflam | Dysman | Mefenamic acid cox | Mefenamic acid trs | Opustan | Ponstan | Ponstan cmx</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Acinic | Aidol | Padomil | Ponstan | Rafreda</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alfoxan | Analgic | Analmin | Beafemic | Eurotan F | Feminar | Fenapon | Fenstan | Filmefen | Gynogesic | Hamitan | Hostan | Medicap | Mefa | Mefacap | Mefamic | Mefen | Mefenac | Mefenam | Mefenama | Mefencid | Mefene | Mefengesic | Mefenstan | Mefeton | Mefic | Metsyn | Napan | Pharmaniaga Mefenamic Acid | Pongesic | Ponsgesic | Ponsis | Ponstal | Ponstamic | Ponstan | Ponstel | Pontacid | Potarlon | Sefmic | Shanamef | Toeefon | U Ponol | Uni-Fenamic</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ponmel</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Abfendol | Allogon | Alpain | Analspec | Anastan | Asam mefenamat | Asimat | Benostan | Bimastan | Bonapons | Cargesik | Cetalmic | Corstanal | Costan | Datan | Dogesic | Dolfenal | Dolodon | Dolorstan | Dolos | Dystan | Etafenin forte | Fargetix | Femisic | Fenamin | Fimestan | Freedol | Gitaramin | Grafamic | Grafix | Inastan | Ipigesia | Kemostan | Lapistan | Licostan | Mectan | Mefamat | Mefast | Mefentan | Mefinal | Mefinter | Mefix | Megastan | Menin | Nichostan | Novastan | Omestan | Opistan | Pehastan | Ponalar | Poncofen | Pondex | Ponsamic | Ponstan | Ponstelax | Solasic | Spartan | Stanalin | Stanza | Stelpon | Teamic | Topgesic | Trifastan | Tropistan | Venic | Witranal | Yekapons</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mefac | Pinalgesic | Ponalgic | Ponmel | Ponstan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Almefkem | Ibuclin p | Medol | Mefac | Mefalgin | Mefalth | Mefanex | Mefanorm | Mefast | Mefentod | Meff p | Mefkind-P | Meflup | Mefrin | Meftal | Meftal p | Mefzen | Mf | Mictal | New zydol | Osra | Ponstan | Sumo mf | Trumef</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Mefedad | Mefenadain | Mefenak | Mefenamic awa | Monstan | Piostan | Ponstal | Ponstamel | Ponstamic | Ponstidin | Remopain</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lysalgo</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Dysman | Fenamic | Fendol | Painex | Pangesic | Ponstan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Asuragin | Bafhameritin m | Barmont hachi | Bonabol | Cystenal | Cystenal tsuruhara | Lumental | Lumental all | Lumental choseido | Mefenamic acid arax | Mefenamic acid ohara | Mefenamic acid showa | Milrest | Mycasaal | Namphen | Neuritorl c | Occorner | Pontal | Retamel | Roihil | Spantac | Takapiron | Toyonectal | Youfenam</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Analmin | Fenamex | Fendol ds | Mefan | Mefdol forte | Mefen | Mefex | Mefnac | Mefnac d.s. | Mefril | Mefsun | Meftal | Meftal p | Nelstan | Ponstan | Ponstan forte | Relisure | Unimefic</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Afmina | Kostan | Mefenamin | Mefenas | Mefental | Megapan | Melfen | Menaroxine | Mental | Meponam | Merinal | Penadon | Polynal | Ponitan | Ponsnal | Ponstan | Ponstel | Ponsten | Ponstil | Pontal | Pontamin | Porisin | Pytal | Roking | Salacin | Tripeace | Union mefenamic acid | Vaquing | Vegabon | Yuhan mefenamic acid | Yuhan pontal</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Fenam forte | Fenamic | Mefac | Mefenam | Ponalgic | Ponstan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fendol | Mefex | Pangesic | Ponstan forte</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ponalar | Ponstan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ponstyl</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acido mefenamico | Artriden | Namifen | Ponstan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel-Mefenamic | Beafemic | Dyfenamic | Fenagesic | Hamitan | Hostan | Medicap | Mefa | Mefa forte | Mefac | Mefacap | Mefcid | Mefemic | Mefen | Mefenama | Mefenamic | Mefenix | Mefetab | Mefic | Melgesic | Napan | Panacid | Pongesic | Ponstan | Ponstel | Pontacid | Pontalon | Sefmic | Triopon | Zeet</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Fanamex | Mefdol | Mefdol forte | Ponstan | Silaxin | Uremine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-mefenamic acid | Ponstan</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Alfoxan | Omatan | Omtan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acido mefenamico | Femidol plus | Mefac | Misstan dm | Rosadol | Tanston</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acidan | Aciflam | Afligec | Agapec | Algastel | Algicap | Algifort | Almefen | Analcid | Analmin | Aprostal | Arthran | Atmose | Avhex | Belfedane | Biogenerics mefenamic acid | Biomef | Boie mefenamic acid | Calibral | Chrisfen | Contofel | Corpugen | Dewymine | Dhanemic | Dolfenal | Dolmetine | Dolorex | Dolsten | Drexaral | Ehpimac | Escandar | Eurostan | Fenady | Fenamax | Fenexan | Fengic | Finox | Flamic | Foralgesia | Fromefen | Gardan | Gisfen | Govim | Harpinac | Hispen | Icelax | Infamix | Inflasic | Iongesic | Isagesic | Istan | Jandrum | Lafayette mefenamic acid | Laffed | Lezpain | Marfen | Maxfield | Mecid | Mecid a | Medianon | Medic aid mefenamic acid | Mefadona | Mefan | Mefedol | Mefedon | Mefein | Mefenamic acid Winthrop | Mefenax | Mefenol | Meferil | Mefivan | Mefostan | Mefranal | Megalin | Megyxan | Melette | Metaflam | Metmic | MEYERF Mefenamic Acid | Mfe | Modilon | Myrefen | Namicor | Naxal | Neostan | Nupain 500 | Pacimic | Parasidon | Penomor | Ponser | Ponstan | Pontaser | Proxyl | Qasar | Ralgec | Rhea mefenamic acid | RiteMED mefenamic acid | Selemic | Selmac | Senflam | Sigarax | Spegic | Stangesic | Suprazen | Suprazen forte | Tamolyn | Tonifen | Totagesic | Traver | Tynostan | Usa-mefenamic acid | Vamgesic | Vandifen | Zanovic | Zapan | Zerrmic | Zestan | Zopan ds</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amic | Amnic | Anapan | Anapen | Benamic | Benamic forte | Boschtan | Constel | Constel forte | Deemac | Delmic | Depane | Dologin | Dolor | Doloron | Durenol | Epostan | Febrin | Fenamic | Fenstan | Fonstal | Fortagesic | Gardan | Glomac | Gripan forte | Kaypan | Mafnol | Mamic | Medocid | Mefacid | Mefacine | Mefad | Mefadil | Mefadon | Mefadon forte | Mefalgic | Mefcid | Mefco | Mefen forte | Mefene | Mefgesic | Meflin | Mefnac | Mefnacine | Mefnax | Mefo | Mefomide | Meforex forte | Meftan | Menamic | Mepon | Mf | Mifnostan forte | Nivastan | Novomic | Obstan | Panamaz | Panamic | Pharmic | Phontan | Pohil | Pohil forte | Ponfab | Pongesic | Ponsac | Ponsic | Ponstan | Ponstil | Prestan | Prinsid | Prinsid forte | Rasmic | Regocid | Rexafenamic | Rinamic | Solacy | Syngesic | Tabrofemic | Wilstan | Zopan</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo-mefen | Mefacit | Ponalar</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ponstel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ponstan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Migranon eva</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fenamic | Fendol DS | Mafepain | Pangesic | Ponstan Forte</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Vidan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acidum Mephenamicum</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Fenam | Fenam forte | Fenamic | Fendol | Mafepain | Pangesic | Ponstan | Tabigesic</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Beafemic | Dyfenamic | Fenagesic | Hostan | Medicap | Mefenix | Mefril | Melgesic | Napan | Nofeb | Ponstan | Pontacid | Pontalon | Pontyl | SP Famic | Zeet</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Pontacid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anacap | Anagan | Anagic | Analgic | Coly | Conamic | Danota | Dismen | Dolfen | Dolfenal | Dymefen | Dyspen | Enamic | Fastan | Feemed | Feemic | Femen | Fena | Fenamic | Fespa | Fevek | Fevest | Fob Namic | Fomanic | Gandin | Gandin DS | Geogesic | Gynogesic | Gynopain | J V Mic | Kressfec 500 | Locpan | Magesic | Manic | Masafen | Matan | Meditan | Mednil | Mefa | Mefamed | Mefamic | Mefec | Mefen | Mefen forte | Mefenac | Mefenan | Mefenstar | Mefmic | Mefnasic | Mefpon | Meftan | Megesic | Mena | Menagal | Menagesic | Menamic | Menopane | Menstat | Meomic | Merofen | Migesic | Mofemed | Nalgesin | Nalgisin | Namic | Namicox | Neopain | Pacamic | Painnox | Panamic | Panfemic | Panfemic-f | Pekaso | Pinmic | Ponamic | Ponatab | Pondnadysmen | Ponfen | Pongesics | Ponmed | Ponmed-r | Ponnac | Ponnesia | Ponsic | Ponstan | Premic | Pronamic | Prostan | Pynamic | Qumefen | Seanamic | Sefmic | Stopen | Sunstan | T.V. Gin | Totagesic | Upna | Vestan | Wocomic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dysman | Fenamyl | Fendol | Fendol ds | Inflamyl | Mefalgic | Mefenal | Ponstan | Ponstyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fenamin | Ponstan | Rolan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bausutoner | Bonstan | Costol | Coton | Cyanton | Femina | Futonyan | Glare | Johnstal | Lotonin | Mefana | Mefegen | Mefeine | Mefen | Mefena | Mefenamic | Mefenamin | Mefentin | Mefeton | Mefic | Mexton | Mispanton | Moton | Painstop | Panthdan | Passton | Paston | Pisuton | Poinstan | Ponstal | Ponstan | Ponsuton | Ponton | Posdan | Posmetan | Poston | Potan | Potarlon | Poton | Poustarn | Presiton | Procoton | Prosten | Puston | Pxiton | Pyston | Seuston | Shuton | Stone | Stopain | Suitone | Suston | Sutan | Suton | Tatonlin | Toeefon | Ton-pass | Tonifen-250 | Tonifen-500 | Tonpass | Twucolin | Warrowsol | Yunstan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acidum Mephenamicum | Amifena ic | Fendol | Mefenaminka</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Alfoxan | Mefena | Mefinal | Meflam | Meflin | Relisure</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ponstil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acido mefenamico | Biomic | Nedran | Ofastan | Ponstan</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Dicintavic | Ponasic | Poncif dhg</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-mefenamic acid | Fenamin | Mefalgic | Ponac | Ponstan | Ponstel | Rolab-mefenamic acid</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Alfoxan | Hostan | Ponstan</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Adco-mefenamic acid | Alfoxan | Alfoxid | Betamef | Ponstan | Varistan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation</i>. 2010;122(24):2619-2633. doi:10.1161/CIR.0b013e318202f701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21640290">
<a name="21640290"></a>Bell AD, Roussin A, Cartier R, et al. The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Can J Cardiol</i>. 2011;27(suppl A):1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/21640290/pubmed" id="21640290" target="_blank">21640290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24663106">
<a name="24663106"></a>Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/24663106/pubmed" id="24663106" target="_blank">24663106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19017521">
<a name="19017521"></a>Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol.</i> 2008;52(18):1502-1517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/19017521/pubmed" id="19017521" target="_blank">19017521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23558845">
<a name="23558845"></a>Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/23558845/pubmed" id="23558845" target="_blank">23558845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31535715">
<a name="31535715"></a>Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD000400. doi:10.1002/14651858.CD000400.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/31535715/pubmed" id="31535715" target="_blank">31535715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4973976">
<a name="4973976"></a>Buchanan RA, Eaton CJ, Koeff ST, et al. The Breast Milk Excretion of Mefenamic Acid. <i>Curr Ther Res Clin Exp</i>. 1968;10(11):592-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/4973976/pubmed" id="4973976" target="_blank">4973976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31273431">
<a name="31273431"></a>Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. <i>Eur J Clin Pharmacol</i>. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/31273431/pubmed" id="31273431" target="_blank">31273431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15225193">
<a name="15225193"></a>de Mello NR, Baracat EC, Tomaz G, et al. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. <i>Acta Obstet Gynecol Scand</i>. 2004;83(7):667-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/15225193/pubmed" id="15225193" target="_blank">15225193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7816793">
<a name="7816793"></a>Delgado J, Simonin G, Servier C, García R, Yoma J. Tolfenamic acid and mefenamic acid in the treatment of primary dysmenorrhoea. <i>Pharmacol Toxicol</i>. 1994;75 Suppl 2:89-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/7816793/pubmed" id="7816793" target="_blank">7816793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6783206">
<a name="6783206"></a>Drury PL, Asirdas LG, Bulger GV. Mefenamic acid nephropathy: further evidence. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6267):865-866. doi:10.1136/bmj.282.6267.865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/6783206/pubmed" id="6783206" target="_blank">6783206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098967">
<a name="23098967"></a>Ferraris VA, Saha SP, Oestreich JH, et al. 2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. <i>Ann Thorac Surg</i>. 2012;94(5):1761-1781.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/23098967/pubmed" id="23098967" target="_blank">23098967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1872778">
<a name="1872778"></a>Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. <i>Aust N Z J Obstet Gynaecol</i>. 1991;31(1):66-70. doi:10.1111/j.1479-828x.1991.tb02769.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/1872778/pubmed" id="1872778" target="_blank">1872778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3783459">
<a name="3783459"></a>Hamaguchi T, Shinkuma D, Yamanaka Y, Mizuno N. Bioavailability of mefenamic acid: influence of food and water intake. <i>J Pharm Sci</i>. 1986;75(9):891-893. doi:10.1002/jps.2600750914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/3783459/pubmed" id="3783459" target="_blank">3783459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2217015">
<a name="2217015"></a>Handa SI, Freestone S. Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism. <i>Postgrad Med J</i>. 1990;66(777):557-559. doi:10.1136/pgmj.66.777.557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/2217015/pubmed" id="2217015" target="_blank">2217015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3680546">
<a name="3680546"></a>Isaacs PE, Sladen GE, Filipe I. Mefenamic acid enteropathy. <i>J Clin Pathol</i>. 1987;40(10):1221-1227. doi:10.1136/jcp.40.10.1221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/3680546/pubmed" id="3680546" target="_blank">3680546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095288">
<a name="29095288"></a>Kaosombatwattana U, Limsrivilai J, Pongpaibul A, Maneerattanaporn M, Charatcharoenwitthaya P. Severe enteropathy with villous atrophy in prolonged mefenamic acid users - a currently under-recognized in previously well-recognized complication: Case report and review of literature. <i>Medicine (Baltimore)</i>. 2017;96(44):e8445. doi:10.1097/MD.0000000000008445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/29095288/pubmed" id="29095288" target="_blank">29095288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaunitz.1">
<a name="Kaunitz.1"></a>Kaunitz AM. Abnormal uterine bleeding in nonpregnant reproductive-age patients: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10654808">
<a name="10654808"></a>Katsinelos P, Dimiropoulos S, Vasiliadis T, Fotiadis G, Xiarchos P, Eugenidis N. Oesophageal ulceration associated with ingestion of mefenamic acid capsules. <i>Eur J Gastroenterol Hepatol</i>. 1999;11(12):1431-1432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/10654808/pubmed" id="10654808" target="_blank">10654808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. <i>Kidney International Supplements</i>. 2013;3:1-150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2620043">
<a name="2620043"></a>Langrick AF, Gunn AD, Livesey H, Whitehead AM. A double-blind placebo-controlled crossover study of mebeverine and mefenamic acid in the treatment of primary dysmenorrhoea. <i>Br J Clin Pract</i>. 1989;43(9):317-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/2620043/pubmed" id="2620043" target="_blank">2620043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2868938">
<a name="2868938"></a>MacKenzie IZ, Graf AK, Mitchell MD. Prostaglandins in the fetal circulation following maternal ingestion of a prostaglandin synthetase inhibitor during mid-pregnancy. <i>Int J Gynaecol Obstet</i>. 1985;23(6):455-458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/2868938/pubmed" id="2868938" target="_blank">2868938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mefenamic acid capsules USP [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; June 2021.</div>
</li>
<li>
<div class="reference">
                  Mefenamic acid capsules [product monograph]. Vaughan, Ontario: AA Pharma Inc; November 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32632965">
<a name="32632965"></a>Ouni B, Fathallah N, Ben-Sayed N, Abdessayed N, Slim R, Ben Salem C. Fixed drug eruption (FDE) induced by mefenamic acid with unusually cross-reactivity to diclofenac: a case report. <i>Br J Clin Pharmacol</i>. 2021;87(3):1582-1583. doi:10.1111/bcp.14448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/32632965/pubmed" id="32632965" target="_blank">32632965</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ponstan (mefenamic acid) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; July 2017.</div>
</li>
<li>
<div class="reference">
                  Ponstel (mefenamic acid) [prescribing information]. Florham Park, NJ: Shionogi Pharma Inc; July 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7265079">
<a name="7265079"></a>Redmond AD. Dyskinesia induced by mefanimic acid? <i>J R Soc Med</i>. 1981;74(7):558-559.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/7265079/pubmed" id="7265079" target="_blank">7265079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16045528">
<a name="16045528"></a>Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. <i>BJOG</i>. 2005;112(8):1121-1125. doi:10.1111/j.1471-0528.2005.00642.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/16045528/pubmed" id="16045528" target="_blank">16045528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3561624">
<a name="3561624"></a>Segasothy M, Thyaparan A, Kamal A, Sivalingam S. Mefenamic acid nephropathy. <i>Nephron</i>. 1987;45(2):156-157. doi:10.1159/000184100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/3561624/pubmed" id="3561624" target="_blank">3561624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3540922">
<a name="3540922"></a>Shepherd AN, Ferguson J, Bewick M, Bouchier IA. Mefenamic acid-induced bullous pemphigoid. <i>Postgrad Med J</i>. 1986;62(723):67-68. doi:10.1136/pgmj.62.723.67<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/3540922/pubmed" id="3540922" target="_blank">3540922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26925883">
<a name="26925883"></a>Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi:10.1038/ajg.2016.41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/26925883/pubmed" id="26925883" target="_blank">26925883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3123043">
<a name="3123043"></a>Tsang BK, Domingo MT, Spence JE, Garner PR, Dudley DK, Oxorn H. Endometrial prostaglandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo. <i>Can J Physiol Pharmacol</i>. 1987;65(10):2081-2084. doi:10.1139/y87-326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/3123043/pubmed" id="3123043" target="_blank">3123043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic</a>. Published October 15, 2020. Accessed October 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1595797">
<a name="1595797"></a>van Eijkeren MA, Christiaens GC, Geuze HJ, Haspels AA, Sixma JJ. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. <i>Am J Obstet Gynecol</i>. 1992;166(5):1419-1428. doi:10.1016/0002-9378(92)91614-g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/1595797/pubmed" id="1595797" target="_blank">1595797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7074483">
<a name="7074483"></a>VanWalraven AA, Edels M, Fong S. Pancreatitis caused by mefenamic acid. <i>Can Med Assoc J</i>. 1982;126(8):894.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/7074483/pubmed" id="7074483" target="_blank">7074483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19700884">
<a name="19700884"></a>Vishwakarma P, Raman GV, Sathyan P. Mefenamic acid-induced bilateral transient myopia, secondary angle closure glaucoma and choroidal detachment. <i>Indian J Ophthalmol</i>. 2009;57(5):398-400. doi:10.4103/0301-4738.55066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefenamic-acid-drug-information/abstract-text/19700884/pubmed" id="19700884" target="_blank">19700884</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9601 Version 332.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
